정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1437 | Recruiting | Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection | SARS-CoV-2 Infection | Biological: Equine COVID-19 Antiserum Drug: Standard of care |
Phase 2 | Bharat Serums and Vaccines Limited | INDUSTRY | 160 | All | 18 Years ~ 65 Years | Jehangir Hospital, Pune, Maharashtra, India |
| 1436 | Completed | Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection | COVID-19 | Drug: Ganovo+ritonavir+/-Interferon nebulization | Phase 4 | The Ninth Hospital of Nanchang, Ascletis Pharmaceuticals Co., Ltd. | OTHER | 11 | All | 18 Years ~ 75 Years | The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China |
| 1435 | Active, not recruiting | Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 | COVID-19 Pneumonia | Biological: COVAX+PPV23;COVAX+IIV4 Biological: COVAX only (1st and 2nd dose) Biological: PPV23 for the 1st dose and IIV4 for the 2nd dose |
Phase 4 | China National Biotec Group Company Limited, Chengdu Institute of Biological Products Co.,Ltd., Changchun Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd, Hubei Provincial Center for Disease Control and Prevention, Guangdong Center for Disease Prevention and Control, Henan Center for Disease Control and Prevention | INDUSTRY | 1404 | All | 18 Years | Guangdong Center for Disease Control and Prevention, Guangzhou, Guangdong, China Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China Hubei Center for Disease Control and Prevention, Wuhan, Hubei, China |
| 1434 | Completed | Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 | Covid19 | Biological: COVAX+IIV4; COVAX+PPV23 Biological: COVAX only (1st and 2nd dose) Biological: IIV4 for the 1st dose and PPV23 for the 2nd dose |
Phase 4 | China National Biotec Group Company Limited, Chengdu Institute of Biological Products Co.,Ltd., Changchun Institute of Biological Products Co., Ltd., Beijing Institute of Biological Products Co Ltd., Sichuan Center for Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanxi Center for Disease Control and Prevention | INDUSTRY | 1133 | All | 18 Years | Sichuan Center for Disease Control and Prevention, Chengdu, China Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China |
| 1433 | Not yet recruiting | Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes | COVID-19 Pneumonia | Biological: COVAX | Phase 4 | China National Biotec Group Company Limited, Hunan Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 1440 | All | 60 Years | Nan'an Center for Disease Control and Prevention, Quanzhou, Fujian, China Yong'an Center for Disease Control and Prevention, Sanming, Fujian, China Youxi Center for Disease Control and Prevention, Sanming, Fujian, China Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China Linli County Center for Disease Control and Prevention, Changde, Hunan, China |
| 1432 | Not yet recruiting | Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes | COVID-19 Pneumonia | Biological: COVAX | Phase 4 | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Hunan Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | INDUSTRY | 1440 | All | 60 Years | Nan'an Center for Disease Control and Prevention, Quanzhou, Fujian, China Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China You County Center for Disease Control and Prevention, Zhuzhou, Hunan, China |
| 1431 | Not yet recruiting | Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes | COVID-19 Pneumonia | Biological: Covid-19 vaccine (0-1-4 schedule) Biological: Covid-19 vaccine (0-1-6 schedule) |
Phase 4 | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Hunan Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 1440 | All | 60 Years | Nan'an Center for Disease Control and Prevention, Quanzhou, Fujian, China Yong'an Center for Disease Control and Prevention, Sanming, Fujian, China Youxi Center for Disease Control and Prevention, Sanming, Fujian, China Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China Linli County Center for Disease Control and Prevention, Changde, Hunan, China |